Naloxone

CAS No:
465-65-6 Category:
  • #LGM Pharma is a Naloxone CAS# 465-65-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 465-65-6
  • AHFC code: 28:10.0
  • Synonyms: 1-N-Allyl-14-hydroxynordihydromorphinone, 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone, 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone, 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one, 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one, BRN 1089071, EINECS 207-365-7, EN 1530 base, HSDB 3279, l-N-Allyl-14-hydroxynordihydromorphinone, l-N-Allyl-7,8-dihydro-14-hydroxynormorphinone, l-Naloxone, Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-, Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-, Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)-, N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon, N-Allyl-noroxymorphone, n-Allylnoroxymorphone, Nalossone, Nalossone [DCIT], Naloxona, Naloxona [INN-Spanish], Naloxone, Naloxone Nasal Spray, Naloxonum, Naloxonum [INN-Latin], Normorphinone, N-allyl-7,8-dihydro-14-hydroxy-, (-)-, NSC 70413, UNII-36B82AMQ7N
  • ATC Code: V03AB15
  • Chemical Formula: C19-H21-N-O4
  • Molecular Weight: 327.378
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB01183
  • SMILES: c12[C,]34[C,,]5([C,H]([N,](CC=C)CC4)Cc2ccc(c1O[C,H]3C(=O)CC5)O)O
  • InChl: 1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
  • PubChem:
  • IUPAC: Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy- (8CI) Morphinan-6-one, 4,5-alpha-epoxy-3,14-dihydroxy-17-(2-propenyl)- Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)- Naloxone

Additional Details

Indication:
For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. It is also indicated for the diagnosis of suspected acute opioid overdose. It may also be used as an adjunctive agent to increase blood pressure in the management of septic shock.
Pharmacodynamics:
Naloxone is an opiate antagonist and prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine. Naloxone is an essentially pure narcotic antagonist, i.e., it does not possess the "agonistic" or morphine-like properties characteristic of other narcotic antagonists; naloxone does not produce respiratory depression, psychotomimetic effects or pupillary constriction. In the absence of narcotics or agonistic effects of other narcotic antagonists, it exhibits essentially no pharmacologic activity. When given intravenously, the onset of action is apparent within 2 minutes. The onset of action is slower if given subcutaneously or intramuscularly. The duration of action also differs between sites of injection and dose.
Mode of Action:
While the mechanism of action of naloxone is not fully understood, the preponderance of evidence suggests that naloxone antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Recently, naloxone has been shown to bind all three opioid receptors (mu, kappa and gamma) but the strongest binding is to the mu receptor.
Metabolism:
Naloxone is hepatically metabolized and primarily undergoes glucuronidation to form naloxone-3-glucuronide.
Toxicity:
LD50, IV administration, mouse = 150 ± 5 mg/kg; LD50, IV administration, rat = 109 ± 4 mg/kg;
General Reference:
FDA labelhttp://www.medscape.com/viewarticle/441915_3
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos